MOR-006: A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation

Project: Research project

Project Details

StatusFinished
Effective start/end date3/15/133/13/15

Funding

  • BioMarin Pharmaceutical Inc. (MOR-006)